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Follicle Stimulating Hormone Receptor and Caveolin

Hypothesis

Results

HEK293-hFSHR cells that are treated with the wild-type (interfering) peptide
will express decreased levels of cAMP. There should be no difference in the
level of cAMP in the cells treated with the mutant peptide and the cells
treated with no peptide.
Tat -WT Caveolin binding motif peptide
Tat -Mutant Caveolin binding motif peptide

Average Difference in cAMP levels at 5 Minutes
175 %

% of initial cAMP levels

Introduction

ygrkkrrqrrrFAFAAALFPIF
ygrkkrrqrrrLALAAALLPIL

Wild type and mutant caveolin binding motifs. The Tat peptide is in small letters and the
hFSHR caveolin binding motif is in capital letters. Mutated residues are in bold.

Other Experiments from the Cohen Lab
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Western Blot analysis of p44 levels in response to hFSH treatment for different times
following pretreatment with WT and MU peptide mimetics of the hFHSR-caveolin
interaction motif.

Current FSHR signaling pathway model & cAMP detection
1a. When FSH binds to FSHR
the G protein alpha subunit
activates adenylyl cyclase
to stimulate production of
cAMP
1b. FSH activates downstream
phosphorylation of p44
MAP Kinase
2. cAMP activates protein
kinase A
3. Protein kinase A activates
the MAP kinases and the
cAMP response element
binding protein (CREB)

●EPAC serves as a highly sensitive
CAMP indicator. When expressed in
mammalian cells, EPAC shows
significant FRET.
●Fluorescence resonance transfer
energy (FRET) is expressed as a ratio
of CFP to YFP.
●FRET decreases in response to CAMP
production and fully recovers in the
presence of CAMP lowering agonists.
●No cAMP = Emission at 530 nm
●CAMP = Emission changes to 480nm

Remove medium and wash with 1X PBS
and take baseline reading

125 %
100 %
75%
50%
25%

0

0. 2

0. 5

1

2

5

20

Concentration of FSH (ng)
No pe pt ide

Bloc king

No n- blo ckin g

This figure compares the ratio of LM1 (480nm, no FRET) to LM2
(530nm, FRET) at t=0 to the ratio of LM1 to LM2 at t = 15 minutes. The
difference in cAMP levels between t=0 and t=15 in each well were then
averaged.

● CREB and p44 pathways measure hFSHR response indirectly. This
experiment attempts to measure hFSHR activation more directly through
monitoring cAMP production

Pretreatment
Aspirate wells and wash with S/F
medium
Introduce WT and MU peptides into
cells
Incubate 1 hour
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Experimental Approach

Prepare 96 well dish of hFSHR-EPAC
cells.
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This figure compares the ratio of LM1 (480nm, no FRET) to LM2
(530nm, FRET) at t=0 to the ratio of LM1 to LM2 at t = 5 minutes. The
difference in cAMP levels between t=0 and t=5 in each well were then
averaged.
Average Difference in cAMP levels at 15 Minutes

Western blot analysis of p-CREB levels in response to hFSH treatment following
pretreatment with different doses of peptide mimetics of the hFSHR-caveolin
interaction motif.

● FSHR is a G-Protein Coupled Receptor (GPCR) activated by FSH
● Located in the membranes of Sertoli Cells in testes and granulosa
cells in ovaries
● FSH aids in follicle maturation and estrogen production in women
and sperm development in men
● The protein caveolin is thought to interact with transmembrane
domain IV (circled) to promote the binding of the receptor to the
caveolae, a type of lipid raft
● Lipid rafts support a diverse group of receptors that are needed at
the cell membrane

Bloc king

Conclusions
● In the presence of the wild type (blocking) peptide, there is an
increase in basal levels of cAMP, which does not support the
original hypothesis. This may suggest that caveolin plays a role
in turning the hFSH receptor off.
● This observation is consistent with the western blot analysis
from the Cohen lab, but inconsistent with known literature that
suggests caveolin blocking peptides have a diminished capacity
to stimulate the receptor (Roh et al, 2014).
● Although it is unclear what role the mutant (non-blocking)
peptide may be playing, our data suggests that the tat mutant
peptide sequence may not be the best control.
● In the future, this experiment should be repeated using a mutant
peptide with a scrambled caveolin binding motif sequence.
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